• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1999 Fiscal Year Final Research Report Summary

関節リウマチのサイトカインおよび血管増殖因子抑制効果に関する基礎的研究-サイトカインおよびVEGFアンチセンス療法による新しい治療戦略-

Research Project

Project/Area Number 10670433
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field 内科学一般
Research InstitutionNIPPON MEDICAL SCHOOL

Principal Investigator

NAGASHIMA Masakazu  Nippon Medical School Dept. Rheumatism, Assistant Professor, 医学部, 講師 (20256952)

Co-Investigator(Kenkyū-buntansha) AONO Hiroyuki  Santen Pharmaceutical Company Ltd., Researcher, 開発研究本部, 主任研究員
ISHIWATA Toshiyuki  Nippon Medical School Dept. Patology, Assistant, 医学部, 助手 (90203041)
Project Period (FY) 1998 – 1999
KeywordsRheumatoid Arthritis / Angiogenesis / Vascular endothelial growth factor (VEGF) / Basic fibroblast growth factor (b-FGF) / Endostatin / Cultured synoviocytes / Disease modifying antirheumatic drugs (DMARDs)
Research Abstract

Angiogenesis and synovial cell poliferation are thought to be essential processes in chronic and developmental arthritis, as well as rheumatoid arthritis (RA). Steroids and disease modifying antirheumatic drugs are most widely used as modifying the clinical course of RA. In particular, We examined whether bucillamine (BUC), gold sodium thiomalate (GST), methotrexate (MTX), salazosulfapyridine (SASP) an dexamethazone (DEX) inhibit the production of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF). Our results indicated that BUC and DEX could alone inhibit the production of VEGF and mRNA, respectively. Next, we investigated the effect of combinations of these DMARDs including BUC, GST, MTX, SASP and DEX on the production of b-FGF and VEGF. None of the DMARDs or DEX could inhibit b-FGF production when give alone, but a combination of SASP and GST inhibited the prodiction of b-FGF in cultured synoviocytes. On the other hand, all of these combinations cou … More ld inhibit VEGF production except the combinationof MTX and SASP. In the peripheral bloos from obtained 129 RA patients, the serum VEGF levels were correlated with CRP (C-reactive protein) and were found to be significantly decreased 6 months after the commencement of medication compared to their levels before. These results in vitro were supported by the observations in the peripheral blood of patients with RA, that is, in vivo.
We mesured the VEGF and b-FGF, and endostatin in peripheral blood and joint fluid obtained from patients with RA and non RA patients using ELISA. The b-FGF and VEGF levels in the peripheral blood and joint fluid of patients with RA were significantly higher than those in the samples from patients without RA, but the endostatin levels were similar and not significantly different between patients with RA and without RA. These results suggested angiogenesis in RA occurs as a result of an imbalance in production between angiogenic growth factors and angiogenesis inhibitors. We will investigate angiogenesis or the inhibitory effects the synovial cell proliferation transplanted in SCID mouse by VEGF antisense or the other angiogenesis inhibitors, like TNP 470. Less

  • Research Products

    (20 results)

All Other

All Publications (20 results)

  • [Publications] Nagashima M, et al: "Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells"Clin Exp Immunol. 116. 360-365 (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Nagashima M, et al: "The imbalance between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis"J Rheumatol. 27(in press). (2000)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Nagashima M, et al: "Combination effects of antirheumatic drugs on vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and pat with rheumatoid arthritis"Br J Rheumatlo. 39(in press). (2000)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Nagashima M, et al: "Expression of κ-opioid receptor mRNA in human peripheral blood lymphocytes and the relationship between its expression and the inflammatory chnges in rheumatoid arthritis"Rheumatol Int.. 20(in press). (2000)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Nagashima M, et al: "IgG rheumatoid factor in early rheumatoid arthritis as a predictor of radiological changes and disease activity"Japanese J Rheumatol. 9. 159-166 (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Nagashima M, et al: "Granulocyte and monocyte apheresis suppresses symptoms of rheumatoid arthritis : a pilot study"Rheumatol Int.. 18. 113-118 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Nagashima M, et al: "Effects of DMARDs on IL-6, b-FGF, VEGF inculturd synovial cells- Basic research of combination therapy-"Arthritis Rheum. 41. S161 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Nagashima M, et al: "Effects of DMARDs on vascular endothelial growth factor in synoviocytes from patients with rheumatoid arthritis"Arthritis Rheum. 41. S161 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 永島正一 等,: "関節リウマチ滑膜培養細胞に対するDMARDsの薬理効果-各種サイトカインに対する抑制効果"臨床薬理. 29. 161-162 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 永島正一 等,: "慢性関節リウマチ-最近の動向Disease modifying antirheumatic drugs(DMARDs)による血管増殖因子およびサイトカイン抑制効果について"別冊整形外科. No.34. 64-68 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Nagashima M. et al: "Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells."Clin Exp Immunol. 116. 360-365 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Nagashima M: "The imbalance between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis."J Rheumatol. 27 (in press). -Nagashima M. et al (2000)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Nagashima M. et al: "Combination effects of antirheumatic drugs on vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis."Br J Rheumatol. 39 (in press). (2000)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Gunji N, Nagashima M, Yoshino S: "Expression of κ-opioid receptor mRNA in human peripheral blood lymphocytes and the relationship between its expression and the inflammatory chnges in rheumatoid arthritis."Rheumatol Int. 20 (in press). (2000)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Nakamura H, Yoshino S, Nagashima M, et al: "IgG rheumatoid factor in early rheumatoid arthritis as a predictor of radiological changes and disease activity."Japanese J Rheumatol. 9. 159-166 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Nagashima M, et al: "Granulocyte and monocyte apheresis suppresses symptoms of rheumatoid arthritis : a pilot study."Rheumatol Int. 18. 113-118 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Nagashima M, et al: "Effects of DMARDs on IL-6, b-FGF, VEGF incultured synovial cells -Basic research of combination therapy-."Arthritis Rheum 1998. 41. S161 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Nagashima M, et al: "Effects of DMARDs ib vascular endothelial growth factor in synoviocytes from patients with rheumatoid arthritis."Arthritis Rheum. 41. S161 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Nagashima M, et al: "Inhibitory effects of disease modifying antirheumatic drugs on several cytokines."Jpn J Clin Pharmacol Ther. 29. 161-162 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Nagashima M, et al: "Inhibitory effects of disease modifying antirheumatic drugs on angiogenic growth factors and several cytokines."Orthopedic Surg. 34. 64-68 (1998)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2001-10-23  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi